Martina Canestraro

632 total citations
16 papers, 415 citations indexed

About

Martina Canestraro is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Martina Canestraro has authored 16 papers receiving a total of 415 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 7 papers in Hematology and 4 papers in Oncology. Recurrent topics in Martina Canestraro's work include Acute Myeloid Leukemia Research (4 papers), Histone Deacetylase Inhibitors Research (3 papers) and Protein Degradation and Inhibitors (3 papers). Martina Canestraro is often cited by papers focused on Acute Myeloid Leukemia Research (4 papers), Histone Deacetylase Inhibitors Research (3 papers) and Protein Degradation and Inhibitors (3 papers). Martina Canestraro collaborates with scholars based in Italy, United States and Hungary. Martina Canestraro's co-authors include Nader G. Abraham, Luca Vanella, Komal Sodhi, Michal L. Schwartzman, Sara Galimberti, Mario Petrini, Vijay L. Manthati, Dong‐Hyun Kim, Sreenivasulu Reddy Koduru and Katherine Gotlinger and has published in prestigious journals such as Journal of Clinical Oncology, Hypertension and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

Martina Canestraro

16 papers receiving 408 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Martina Canestraro Italy 10 217 117 75 69 60 16 415
Samantha D. Pauls Canada 10 153 0.7× 94 0.8× 47 0.6× 23 0.3× 17 0.3× 17 416
Claude Vieu France 14 235 1.1× 116 1.0× 47 0.6× 250 3.6× 21 0.3× 20 716
Antonella Zampolli Italy 12 121 0.6× 66 0.6× 13 0.2× 31 0.4× 109 1.8× 19 619
Ashok Chaudhary United States 10 327 1.5× 59 0.5× 32 0.4× 13 0.2× 24 0.4× 32 764
Yayoi Hosoki Japan 10 254 1.2× 80 0.7× 104 1.4× 122 1.8× 128 2.1× 13 688
Takaharu Yoh Japan 10 217 1.0× 44 0.4× 57 0.8× 75 1.1× 31 0.5× 15 641
Justin M. Cole United States 12 230 1.1× 48 0.4× 11 0.1× 155 2.2× 43 0.7× 18 628
Diogo B. Peruchetti Brazil 15 143 0.7× 33 0.3× 34 0.5× 43 0.6× 14 0.2× 37 458
Jean‐Marie Frenoux France 9 121 0.6× 66 0.6× 59 0.8× 41 0.6× 15 0.3× 13 502
L Laster United States 15 132 0.6× 90 0.8× 39 0.5× 54 0.8× 33 0.6× 20 550

Countries citing papers authored by Martina Canestraro

Since Specialization
Citations

This map shows the geographic impact of Martina Canestraro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martina Canestraro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martina Canestraro more than expected).

Fields of papers citing papers by Martina Canestraro

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martina Canestraro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martina Canestraro. The network helps show where Martina Canestraro may publish in the future.

Co-authorship network of co-authors of Martina Canestraro

This figure shows the co-authorship network connecting the top 25 collaborators of Martina Canestraro. A scholar is included among the top collaborators of Martina Canestraro based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martina Canestraro. Martina Canestraro is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Robertson, Ian B., Nele M. G. Dieckmann, Martina Canestraro, et al.. (2023). Tuning the potency and selectivity of ImmTAC molecules by affinity modulation. Clinical & Experimental Immunology. 215(2). 105–119. 9 indexed citations
2.
Hoffmann, Michèle J., Martin Campbell, Klaus Pechhold, et al.. (2023). AFNT-211: An FAS-41BB–enhanced TCR-T cell therapy with stem-like properties targeting KRAS G12V-expressing solid tumors.. Journal of Clinical Oncology. 41(16_suppl). 2543–2543. 1 indexed citations
3.
Cauchy, Pierre, Sally James, Joaquin Zacarías-Cabeza, et al.. (2015). Chronic FLT3-ITD Signaling in Acute Myeloid Leukemia Is Connected to a Specific Chromatin Signature. Cell Reports. 12(5). 821–836. 48 indexed citations
4.
Vanella, Luca, Martina Canestraro, Craig R. Lee, et al.. (2015). Soluble epoxide hydrolase null mice exhibit female and male differences in regulation of vascular homeostasis. Prostaglandins & Other Lipid Mediators. 120. 139–147. 18 indexed citations
5.
Galimberti, Sara, Martina Canestraro, Elena Ciabatti, et al.. (2010). HISTONE ACETHYLASE INHIBITORS VORINOSTAT AND ITF2357 EXERT A DEMETHYLATINGEFFECT ON THE MYELOMA CELL LINE U266. Haematologica. 95. 72–72. 2 indexed citations
6.
Canestraro, Martina, Sara Galimberti, Hakan Savlı, et al.. (2010). Synergistic antiproliferative effect of arsenic trioxide combined with bortezomib in HL60 cell line and primary blasts from patients affected by myeloproliferative disorders. Cancer Genetics and Cytogenetics. 199(2). 110–120. 20 indexed citations
7.
Galimberti, Sara, Martina Canestraro, Hakan Savlı, et al.. (2010). ITF2357 interferes with apoptosis and inflammatory pathways in the HL-60 model: a gene expression study.. PubMed. 30(11). 4525–35. 10 indexed citations
8.
Burgess, Angela, Ming Li, Luca Vanella, et al.. (2010). Adipocyte Heme Oxygenase-1 Induction Attenuates Metabolic Syndrome in Both Male and Female Obese Mice. Hypertension. 56(6). 1124–1130. 95 indexed citations
9.
Sodhi, Komal, Kazuyoshi Inoue, Katherine Gotlinger, et al.. (2009). Epoxyeicosatrienoic Acid Agonist Rescues the Metabolic Syndrome Phenotype of HO-2-Null Mice. Journal of Pharmacology and Experimental Therapeutics. 331(3). 906–916. 124 indexed citations
10.
Petrini, Marina, Sara Galimberti, Martina Canestraro, et al.. (2008). Histone deacetylase inhibitor ITF2357 is effective on the P39 cells. A gene expression study. Journal of Clinical Oncology. 26(15_suppl). 18024–18024. 3 indexed citations
11.
Savlı, Hakan, Sara Galimberti, Martina Canestraro, et al.. (2008). Bortezomib combined with histone deacetylase inhibitor ITF2357 or arsenic trioxide exerts aynergistic anti-proliferative and pro-apoptotic effect on P39 cells. Journal of Clinical Oncology. 26(15_suppl). 18022–18022. 1 indexed citations
12.
Canestraro, Martina, Rossana Maffei, Roberto Marasca, et al.. (2007). SAHA INHIBITS PROLIFERATION AND INDUCES APOPTOSIS IN A MEGAKARYOBLASTICCELL LINE AND SYNERGISTICALLY INTERCATCS WITH THE PORTEASOME INHIBITORBORTEZOMIB.. Haematologica. 92. 123–123. 1 indexed citations
13.
Galimberti, Sara, Martina Canestraro, Eugenio Ciancia, et al.. (2007). PS-341 (BORTEZOMIB) INHIBITS BOTH PROLIFERATION OF MEGAKARYOBLASTIC CELLSIN VITRO AND MK COLONIES PRODUCTION IN PATIENTS AFFECTED BY IDIOPATHICMYELOFIBROSIS. Haematologica. 92. 25–25. 2 indexed citations
14.
Galimberti, Sara, Bálint Nagy, E. Benedetti, et al.. (2007). Evaluation of theMDR1,ABCG2,Topoisomerases IIαandGSTπgene expression in patients affected by aggressive mantle cell lymphoma treated by the R-Hyper-CVAD regimen. Leukemia & lymphoma. 48(8). 1502–1509. 10 indexed citations
15.
Galimberti, Sara, Martina Canestraro, Simone Pacini, et al.. (2007). PS-341 (Bortezomib) inhibits proliferation and induces apoptosis of megakaryoblastic MO7-e cells. Leukemia Research. 32(1). 103–112. 13 indexed citations
16.
Orciuolo, Enrico, Marta Stanzani, Martina Canestraro, et al.. (2007). Effectsof Aspergillus fumigatusgliotoxin and methylprednisolone on human neutrophils: implications for the pathogenesis of invasive aspergillosis. Journal of Leukocyte Biology. 82(4). 839–848. 58 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Samantha D. Pauls Breakdown of academic impact, for papers by Claude Vieu Breakdown of academic impact, for papers by Antonella Zampolli Breakdown of academic impact, for papers by Ashok Chaudhary Breakdown of academic impact, for papers by Yayoi Hosoki Breakdown of academic impact, for papers by Takaharu Yoh Breakdown of academic impact, for papers by Justin M. Cole Breakdown of academic impact, for papers by Diogo B. Peruchetti Breakdown of academic impact, for papers by Jean‐Marie Frenoux Breakdown of academic impact, for papers by L Laster
Rankless by CCL
2026